Bortezomib beneficial in graft-versus-host disease prophylaxis

August 8, 2012
Bortezomib beneficial in graft-versus-host disease prophylaxis
Patients with hematologic malignancies undergoing an HLA-mismatched unrelated donor reduced-intensity conditioning hematopoietic stem cell transplantation may benefit from a prophylactic, short-course, bortezomib-based regimen to reduce the incidence of graft-versus-host disease, according to research published online Aug. 6 in the Journal of Clinical Oncology.

(HealthDay) -- Patients with hematologic malignancies undergoing an HLA-mismatched unrelated donor (MMUD) reduced-intensity conditioning (RIC) hematopoietic stem cell transplantation (HSCT) may benefit from a prophylactic, short-course, bortezomib-based regimen to reduce the incidence of graft-versus-host disease (GVHD), according to research published online Aug. 6 in the Journal of Clinical Oncology.

John Koreth, M.B.B.S., D.Phil., of the Dana-Farber Cancer Institute in Boston, and colleagues conducted a prospective, phase I/II trial involving 45 patients who underwent MMUD RIC HSCT. Participants underwent a short-course GVHD prophylaxis regimen consisting of bortezomib administered on days one, four, and seven following peripheral stem cell infusion plus methotrexate and tacrolimus.

The researchers found that the cumulative incidence of grade 2 to 4 GVHD over 180 days was 22 percent and the one-year cumulative incidence was 29 percent for chronic GVHD. At two years, deaths due to relapse occurred in 38 percent, and nonrelapse mortality was 11 percent. Progression-free survival and overall survival were 51 and 64 percent, respectively, at two years. The rates of nonrelapse mortality, acute and chronic GVHD, and survival were similar to those of contemporaneous HLA-matched RIC HSCT.

"In conclusion, short-course, bortezomib-based GVHD prophylaxis appears safe and efficacious in HLA-mismatched RIC transplantation, with encouraging survival," the authors write. "Importantly, bortezomib-based MMUD transplantation achieved clinical outcomes comparable to HLA-matched transplantation, along with enhancement of various immune reconstitution parameters."

One author disclosed financial ties to Millennium Pharmaceuticals, which partially funded the study and develops and markets .

Explore further: Researchers test drug combinations to prevent graft vs. host disease

More information: Abstract
Full Text (subscription or payment may be required)
Editorial

Related Stories

Researchers test drug combinations to prevent graft vs. host disease

June 26, 2012
Researchers at Moffitt Cancer Center have conducted a clinical trial aimed at preventing graft vs. host disease (GVHD) in patients who have received hematopoietic (blood) cell transplants (HCT). The study, comparing the drug ...

HIV drug reduces graft-versus-host disease in stem cell transplant patients

December 13, 2011
An HIV drug that redirects immune cell traffic appears to significantly reduce the dangerous complication graft-versus-host disease (GvHD) in blood cancer patients following allogeneic stem cell transplantation (ASCT), according ...

Mini-molecule governs severity of acute graft vs. host disease, study finds

March 12, 2012
Researchers have identified a molecule that helps control the severity of graft-versus-host disease, a life-threatening complication for many leukemia patients who receive a bone-marrow transplant.

Antibodies from rabbits improve survival and relapse outcomes of leukemia and myelodysplasia

July 6, 2012
Researchers at Virginia Commonwealth University (VCU) Massey Cancer Center's Bone Marrow Transplant Program have demonstrated that the use of antibodies derived from rabbits can improve the survival and relapse outcomes of ...

HIV drug reduces graft-vs.-host disease in bone marrow transplant patients

July 11, 2012
An HIV drug that redirects immune cell traffic significantly reduces the incidence of a dangerous complication that often follows bone marrow transplants for blood cancer patients, according to research from the Perelman ...

Recommended for you

Stem cell therapy attacks cancer by targeting unique tissue stiffness

July 26, 2017
A stem cell-based method created by University of California, Irvine scientists can selectively target and kill cancerous tissue while preventing some of the toxic side effects of chemotherapy by treating the disease in a ...

Understanding cell segregation mechanisms that help prevent cancer spread

July 26, 2017
Scientists have uncovered how cells are kept in the right place as the body develops, which may shed light on what causes invasive cancer cells to migrate.

Study uncovers potential 'silver bullet' for preventing and treating colon cancer

July 26, 2017
In preclinical experiments, researchers at VCU Massey Cancer Center have uncovered a new way in which colon cancer develops, as well as a potential "silver bullet" for preventing and treating it. The findings may extend to ...

Compound shows promise in treating melanoma

July 26, 2017
While past attempts to treat melanoma failed to meet expectations, an international team of researchers are hopeful that a compound they tested on both mice and on human cells in a petri dish takes a positive step toward ...

Study may explain failure of retinoic acid trials against breast cancer

July 25, 2017
Estrogen-positive breast cancers are often treated with anti-estrogen therapies. But about half of these cancers contain a subpopulation of cells marked by the protein cytokeratin 5 (CK5), which resists treatment—and breast ...

Breaking the genetic resistance of lung cancer and melanoma

July 25, 2017
Researchers from Monash University and the Memorial Sloan Kettering Cancer Center (MSKCC, New York) have discovered why some cancers – particularly lung cancer and melanoma – are able to quickly develop deadly resistance ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.